Literature DB >> 26806036

Effect of spinal monoaminergic neuronal system dysfunction on pain threshold in rats, and the analgesic effect of serotonin and norepinephrine reuptake inhibitors.

Ryuta Tamano1, Mitsuhiro Ishida2, Toshiyuki Asaki1, Minoru Hasegawa1, Shunji Shinohara3.   

Abstract

Dysfunction in the central serotonin (5-HT) and norepinephrine (NE) systems cause depression and pain. Descending spinal pain modulatory pathways are important in the analgesic mechanisms of antidepressants, particularly serotonin and norepinephrine reuptake inhibitors (SNRIs). While many non-clinical studies have demonstrated the roles of central monoaminergic systems in pain, there is little evidence to illuminate the direct contribution of spinal descending pain modulatory systems independently of depressive-like behavior. To examine the effects of dysfunction of spinal monoaminergic systems on pain sensitivity, we established a rat chronic pain model by administering lumbar-intrathecal reserpine to minimize its influence on brain. Lumbar-intrathecal reserpine evoked persistent mechanical hypersensitivity and corresponding reductions in spinal 5-HT and NE concentrations (from 767.2 to 241.6ng/g and from 455.9 to 41.7ng/g, respectively after reserpine 30nmol). Lumbar-intrathecal reserpine did not deplete brain monoamines or bring about depressive-like behavior in the forced swim test. Spinal monoamines depletion-induced pain sensitivity was ameliorated by lumbar-intrathecal administration of the SNRIs (duloxetine and milnacipran) in dose-dependent manners. These suggest that increased pain sensitivity could be induced by dysfunction solely of the descending pain modulatory system, regardless of depressive-like behavior, and lumbar-intrathecal administration of SNRIs could ameliorate the pain sensitivity which might be mediated by affecting the descending pain modulatory system in the spinal cord, not via their antidepressant effects.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Depression; Descending pain modulatory system; Monoamine; Pain; Reserpine; SNRI

Mesh:

Substances:

Year:  2016        PMID: 26806036     DOI: 10.1016/j.neulet.2016.01.025

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

Review 1.  Pharmacological Management of Chronic Pelvic Pain in Women.

Authors:  Erin T Carey; Sara R Till; Sawsan As-Sanie
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

2.  Contribution of amygdala CRF neurons to chronic pain.

Authors:  Matthew Andreoli; Tanvi Marketkar; Eugene Dimitrov
Journal:  Exp Neurol       Date:  2017-08-19       Impact factor: 5.330

Review 3.  The plasticity of descending controls in pain: translational probing.

Authors:  Kirsty Bannister; A H Dickenson
Journal:  J Physiol       Date:  2017-05-26       Impact factor: 5.182

4.  Role of Etanercept and Infliximab on Nociceptive Changes Induced by the Experimental Model of Fibromyalgia.

Authors:  Marika Cordaro; Rosalba Siracusa; Ramona D'Amico; Tiziana Genovese; Gianluca Franco; Ylenia Marino; Davide Di Paola; Salvatore Cuzzocrea; Daniela Impellizzeri; Rosanna Di Paola; Roberta Fusco
Journal:  Int J Mol Sci       Date:  2022-05-30       Impact factor: 6.208

Review 5.  Analgesic Alkaloids Derived From Traditional Chinese Medicine in Pain Management.

Authors:  Wei Jiang; Mingze Tang; Limin Yang; Xu Zhao; Jun Gao; Yue Jiao; Tao Li; Cai Tie; Tianle Gao; Yanxing Han; Jian-Dong Jiang
Journal:  Front Pharmacol       Date:  2022-05-10       Impact factor: 5.988

6.  Study of analgesic effect of earthworm extract.

Authors:  Wei Luo; Zhen-Han Deng; Rui Li; Guo Cheng; Ronak Naveenchandra Kotian; Yu-Sheng Li; Wen-Ping Li
Journal:  Biosci Rep       Date:  2018-01-25       Impact factor: 3.840

7.  The Effect of Pain Catastrophizing on Depression among Older Korean Adults with Chronic Pain: The Mediating Role of Chronic Pain Interference and Sleep Quality.

Authors:  Kyoung-Eun Lee; Hyunju Ryu; Sun Ju Chang
Journal:  Int J Environ Res Public Health       Date:  2020-11-24       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.